Business & Finance
Business and Finance
Business and Finance
Wed, August 12, 2009
Tue, August 11, 2009 Allon Therapeutics Inc.: Allon CEO to Present at Canaccord Adams Global Growth Conference
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 11, 2009) - Allon Therapeutics Inc. (TSX:NPC) has announced that President and CEO Gordon McCauley will present the Company's business progress tomorrow morning at 8:30 a.m. EDT at the Canaccord Adams 29th Annual Global Growth Conference in Boston, MA.
Allon achieved a major milestone July 9 when it released top-line Phase IIa clinical trial data demonstrating that its lead neuroprotective drug candidate, davunetide, has a statistically significant impact on the capacity of schizophrenia patients to carry out important activities in their daily lives.
This data from schizophrenia patients reconfirms the activity of davunetide in human neurological diseases. Last year another Allon's Phase IIa clinical trial data showed that davunetide has a positive impact on memory function in patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer's disease (AD).
The presentation is being webcast live at [ http://www.wsw.com/webcast/canaccord/npc.to/ ].
The presentation will be immediately archived and available for viewing for three months after the live webcast.
Canaccord Adams is a financial services firm with offices in the United States, Canada, and the United Kingdom. The firm hosts conferences such as this one to bring together institutions and issuers.
About Allon
Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on developing the first drugs that impact the progression of neurodegenerative diseases. Allon's drug davunetide has demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer's disease, and schizophrenia-related cognitive impairment. Allon has Phase II human efficacy programs pursuing large underserved markets: Alzheimer's disease, frontotemporal dementia, and schizophrenia-related cognitive impairment. The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuro Protection CompanyTM) and based in Vancouver. For additional information please visit the Company's website: [ www.allontherapeutics.com ].
Forward Looking Statements
Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. While forward-looking statements represent management's outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, Allon's early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which Allon may eventually develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and Allon's dependence on collaborative partners and contract research organizations. These factors can be reviewed in Allon's public filings at [ www.SEDAR.com ] and should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements and Allon disclaims any obligation to update or announce changes in any such factors except in its periodic filings.
